Integrated Graphene has announced it will be investing Â£8 million (around USD$9,496,000) to scale up its manufacturing process for the commercial production of graphene.
Integrated Graphene developed a commercially viable graphene manufacturing process that is currently scaled to high volumes. It is claimed that this process eliminates the scale-up challenges associated with CVD graphene and graphene powder. The Company is also designing manufacturing processes for companies to effectively bolt-on to existing lines, and it also has a team dedicated to supporting organizations to adapt graphene technologies for their products.
The Companyâs investment plan will focus on scaling-up the manufacturing of its graphene enhanced electrodes and super capacitors which are currently being used in human diagnostics point of care testing and smart label asset tracking applications.
These printable electronic products include the Gii-Sens which offers an effective sensor material for the human diagnostics market and Gii-Cap which targets 10% of $500 billion battery market, with the potential to remove 60 million batteries from being thrown away every year. The company will also increase capital expenditure in its next generation pilot line to allow rapid market expansion of Gii- Sens and Gii-Cap.
Beginning with graphene electrodes and supercapacitors, Integrated Graphene will first use its manufacturing technology at its new facility in Stirling, Scotland, before being distributed around the world to partners.
Integrated Graphene also plans to triple its employees over the next three years.
The investment follows Integrated Grapheneâs Series A in November 2020, led by investors Par Equity and Archangels for an undisclosed amount.